




























































Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways 
in controlling growth and sensitivity to therapy-implications for
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The Ras/Raf/MEK/ERK and Ras/PI3K/PTEN/Akt/ 
mTOR signaling pathways have been shown over the 
past 25 years to play key roles in the transmission of 
proliferative signals from membrane bound receptors. 
Mutations can occur in the genes encoding pathway 
constituents (e.g.,  RAS,  RAF,  PIK3CA,  PTEN,  AKT, 
TSC1, TSC2) or in upstream receptors which activate 
these pathways. These pathways relay this information 
through interactions with various other proteins to the 
nucleus to control gene expression [1-13]. This review 
will discuss how these pathways may be aberrantly 
regulated by either upstream mutations/amplification or 
by intrinsic mutations of key components of these 
signaling pathways. Elevated levels of activated 
components of these pathways are often associated with 
poor prognosis in cancer patients or premature aging [2-
5, 7]. Increased expression of signaling pathways can 
also be correlated with altered sensitivity to targeted 
therapy compared to patients that do not exhibit 
elevated expression [2-4]. Inhibition of Raf, MEK, 
PI3K, Akt and mTOR may prove useful in cancer 
treatment as well as in preventing or suppressing 
cellular aging. These observations have propelled the 
pharmaceutical industry to develop inhibitors that target 
key components of these pathways. 
 
  The Ras/Raf/MEK/ERK and Ras/PI3K/PTEN/Akt/ 
mTOR signaling pathways consist of kinases cascades 
that are regulated by phosphorylation and de-
phosphorylation by specific kinases, phosphatases as 
well as GTP/GDP exchange proteins, adaptor proteins 
and scaffolding proteins. The regulation of these 
cascades can be much like the axiom of real estate, 
“location-location-location”, as the membrane 
localization of these components is often critical for 
their activity, even though some members of these 
pathways can function in other cellular regions (e.g., 
mitochondrion, nucleus). Indeed, one emerging 
observation in both extracellular signal-regulated kinase 
1 and 2 (ERK1/2) and mammalian target of rapamycin 
(mTOR) signaling is the realization that pathways 
generate specific biological responses dependent upon 
where in the cell the signal originates [12]. For 
example, phosphorylation of both epidermal growth 
factor receptor (EGFR) and cytosolic phospholipase 
A(2) [cPLA(2)] is most prominent when ERK1/2 is 
activated from lipid rafts, whereas p90 Ribosomal S6 
kinase-1 (p90
Rsk-1) is mainly activated by Ras signals 
emanating from disordered membranes. This substrate 
selectivity is governed by the participation of different 
scaffold proteins that distinctively couple ERK1/2, 
activated at defined subcellular domains, to specific 
substrates. Ras subcellular localization can determine 
substrate specificity through distinct utilization of 
scaffold proteins [1,6,12]. Clearly the subcellular 
localization of pathway components and the presence of 
various adaptor and scaffolding molecules are critical 
for the activity of these pathways. The regulation and 
function of these two pathways will be concisely 
reviewed as well as the effects of genetic mutations that 
are important in human cancer. 
 
The Ras/Raf/MEK/ERK Pathway 
 
An introductory overview of the Ras/Raf/MEK/ERK 
pathway is presented in Figure 1. Also outlined in this 
figure are common sites of intervention with signal 
transduction inhibitors. Many of these inhibitors have 
been evaluated in various clinical trials and some are 
currently being used to treat patients with specific 
cancers. Extensive reviews of many inhibitors targeting 
these pathways have been recently published [2-4]. This 
figure serves as a starting reference point for 
understanding the flow of information through the 
Ras/Raf/MEK/ERK pathway from a growth factor to a 
specific receptor to phosphorylation of appropriate 
transcription factors in the nucleus, which modulate the 
expression of key genes [7-11]. The effects of this 
pathway on the translational apparatus are also 
diagrammed. Often mRNAs encoding growth factors 
are  entitled  “weak”  mRNAs  and  require  the          
effects of the Ras/Raf/MEK/ERK and Ras/PI3K/ 
PTEN/Akt/mTOR pathways for efficient translation 
[2,4,11]. As an example, we present the autocrine 
production of a growth factor. Importantly, many 
components and interacting members of this pathway 
are also present as mutated forms in the genomes of 
retroviruses that induced cancer in experimental 
animals. Thus there have always been direct pivotal 
links of this pathway with malignancy. 
 
After growth factor/cytokine/mitogen stimulation of the 
appropriate (cognate) receptor, a Src homology 2 
domain containing protein (Shc) adaptor protein 
becomes associated with the C-terminus of the specific 
activated growth factor receptor (e.g., vascular 
endothelial growth factor receptor [VEGFR], epidermal 
growth factor receptor [EGFR], insulin like growth 
factor-1  receptor [IGF-1R] and many others) [2-4]. Shc 
recruits the Grb2 protein and the son of sevenless (SOS) 
homolog protein, resulting in the loading of membrane-
bound Ras with GTP [7]. Ras can also be activated by 
growth factor receptor tyrosine kinases [GFRTK], such 
as insulin receptor (IR), via intermediates like insulin 
receptor substrate (IRS) proteins that bind growth factor 
receptor-bound protein 2 [7,8]. Ras:GTP then recruits 
Raf to the membrane where it becomes activated, likely 
via a Src-family tyrosine (Y) kinase [9]. At this point 
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pointed out that both Ras and Raf are members of multi-
gene families and there are three Ras members (Ki-Ras, 
N-Ras and Ha-Ras) [7] and three Raf members (B-Raf, 
Raf-1 [a.k.a c-Raf] and A-Raf) [9].  Raf is responsible for 
serine/threonine (S/T) phosphorylation of mitogen-
activated protein kinase kinase-1 (MEK1) [2,3,7]. MEK1 
phosphorylates ERK1 and 2 at specific T and Y residues 
[10]. Activated ERK1 and ERK2 serine S/T kinases 
phosphorylate and activate a variety of substrates, 
including p90
Rsk1 [2,3,7,10]. ERK1/2 has many 
downstream and even upstream substrates (see below). 
p90
Rsk1 can activate the cAMP response element binding 
protein (CREB) transcription factor [13]. 
 
The number of ERK1/2 targets is easily in the hundreds 
(>600). Thus suppression of MEK and ERK activities 
will have profound effects on cell growth and aging. 
Activated ERK can also phosphorylate B-Raf, Raf-1 
and MEK1 which alter their activity (Figure 1). 
Depending upon the site phosphorylated on Raf-1, ERK 
phosphorylation can either enhance [14] or inhibit [15] 
Raf-1 activity. In contrast, when B-Raf [16] or MEK1 
[17] are phosphorylated by ERK, their activity 
decreases. These phosphorylation events serve to alter 
the stability and/or activities of the proteins. This is the 
first discussion of feed-back loops which will become 
important in consideration of whether to just target 
MEK or to target both Raf and MEK in various cancers. 
It is important that the reader realize that certain 
phosphorylation events can either inhibit or repress the 
activity of the affected protein. This often depends on 
the particular residue phosphorylated on the protein 
which can confer a different configuration to the protein 
or target the protein to a different subcellular 
localization that may result in proteasomal degradation. 
Furthermore, as previously mentioned, certain 
phosphorylation events will actually serve to shut off or 
slow down the pathway. Thus protein phosphorylation 
by the Ras/Raf/MEK/ERK pathway is a very intricate 
process which serves to fine tune the signal often 
originating from a growth factor or mitogens. 
 
Activated ERK can translocate to the nucleus and 
phosphorylate additional transcription factors, such as 
Elk-1, CREB, Fos and globin transcription factor 1 
(Gata-1) and others [2-4, 14,18], that bind promoters of 
many genes, including growth factor and cytokine genes 
that are important in promoting growth and preventing 
apoptosis of multiple cell types. Under certain 
circumstances, aberrant regulation of this pathway can 
contribute to abnormal cellular proliferation which may 
lead to many abnormalities including; autocrine 
transformation, drug resistance, senescence or 
premature aging [2,4,5,19].  
The Ras/PI3K/PTEN/Akt/mTOR Pathway 
 
An introductory overview of the Ras/PI3K/PTEN/ 
Akt/mTOR pathway is presented in Figure 2. Also 
outlined in this diagram are common sites of 
intervention with signal transduction inhibitors. Many 
of these inhibitors have been evaluated in various 
clinical trials and some are currently being used to treat 
patients with specific cancers. Extensive reviews of 
many inhibitors targeting these pathways have been 
recently published [2,4,19,20].  Phosphatidylinositol-3-
kinase (PI3K) is a heterodimeric protein with an 85-kDa 
regulatory subunit and a 110-kDa catalytic subunit 
(PIK3CA) [20,21].  PI3K serves to phosphorylate a 
series of membrane phospholipids including 
phosphatidylinositol 4-phosphate (PtdIns(4)P) and 
phosphatidylinositol 4,5-bisphosphate (PtdIns(4,5)P2), 
catalyzing the transfer of ATP-derived phosphate to the 
D-3 position of the inositol ring of membrane 
phosphoinositides, thereby forming the second 
messenger lipids phosphatidylinositol 3,4-bisphosphate 
(PtdIns(3,4)P2) and phosphatidylinositol 3,4,5-
trisphosphate (PtdIns(3,4,5)P3) [4,19,20]. Most often, 
PI3K is activated via the binding of a ligand to its 
cognate receptor, whereby p85 associates with 
phosphorylated tyrosine residues on the receptor via a 
Src-homology 2 (SH2) domain. After association with 
the receptor, the p110 catalytic subunit then transfers 
phosphate groups to the aforementioned membrane 
phospholipids [4,19,20].  It is these lipids, specifically 
PtdIns(3,4,5)P3, that attract a series of kinases to the 
plasma membrane thereby initiating the signaling 
cascade [4,19,20].  
 
Downstream of PI3K is the primary effector molecule 
of the PI3K signaling cascade, Akt/ protein kinase B 
(PKB). Akt was originally discovered as the cellular 
homologue of the transforming retrovirus AKT8 and as 
a kinase with properties similar to protein kinases A and 
C
  [4,19,21,22]. Akt contains an amino-terminal 
pleckstrin homology (PH) domain that serves to target 
the protein to the membrane for activation [21,22]. 
Within its central region, Akt has a large kinase domain 
and is flanked on the carboxy-terminus by hydrophobic 
and proline-rich regions [22].  Akt is activated via 
phosphorylation of two residues: T308 and S473.   
 
The phosphotidylinositide-dependent kinases (PDKs) 
are responsible for activation of Akt. PDK1 is the 
kinase responsible for phosphorylation of T308 [23]. 
Akt is also phosphorylated by the mammalian target of 
Rapamycin (mTOR) complex referred to as 
(Rapamycin-insensitive companion of mTOR/mLST8 
complex) mTORC2 [4,19] (See Figures 2 & 3).     
Before 
 its  discovery,  the  activity  responsible  for  this  
   








































































































































while  phosphorylation  of  some  molecules  by  certain  kinases  (e.g., β ‐ catenin  by  Akt)  results  in  their  activation  (nuclear 
translocation,  indicated  in  green  box).  The  Ras/PI3K/PTEN/Akt/mTOR  pathway  plays  a  key  role  in  regulating  p53  activity 
(indicated  in  purple  diamond)  by  phosphorylating  MDM2  (indicated  in  red  oval)  which  controls  the  stability  of  p53  by 
ubiquitination.  The  Ras/PI3K/PTEN/Akt/mTOR  pathway  plays  a  key  role  in  regulating  critical  proteins  involved  in  protein 
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Therefore, phosphorylation of Akt is somewhat 
complicated as it is phosphorylated by a complex that 
lies downstream of activated Akt itself [4,19]. Thus, as 
with the Ras/Raf/MEK/ERK pathway, there are 
feedback loops that serve to regulate the 
Ras/PI3K/PTEN/Akt/mTOR pathway. Once activated, 
Akt leaves the cell membrane to phosphorylate 
intracellular substrates. 
 
After activation, Akt is able to translocate to the nucleus
 
[4,19,24] where it affects the activity of a number of 
transcriptional regulators. CREB [25], E2F [26], nuclear 
factor kappa from B cells (NF-κB) via inhibitor kappa B 
protein kinase (Iκ-K) [27], the forkhead transcription 
factors
  [28] and murine double minute 2 (MDM2) 
which regulates p53 activity. These are all either direct 
or indirect substrates of Akt and each can regulate 
cellular proliferation, survival and epithelial 
mesenchymal transition (EMT) [4,11,19,28-31]. Aside 
from transcription factors, Akt is able to target a number 
of other molecules to affect the survival state of the cell 
including: the pro-apoptotic molecule Bcl-2-associated 
death promoter (BAD)
  [29], and glycogen-synthase 
kinase-3β (GSK-3β) [30]. GSK-3β regulates -catenin 
protein stability. Hence the PI3K/PTEN/Akt/mTOR 
pathway is connected to the Wnt/-catenin, p53 and 
many additional pathways (Figure 3). 
 
Negative regulation of the PI3K pathway is primarily 
accomplished through the action of the phosphatase and 
tensin homologue deleted on chromosome ten (PTEN) 
tumor suppressor proteins. PTEN encodes a lipid and 
protein phosphatase whose primary lipid substrate is 
PtdIns(3,4,5)P3  [31-39]. The purported protein 
substrate(s) of PTEN are more varied, including focal 
adhesion kinase (FAK), the Shc exchange protein and 
the transcriptional regulators ETS-2 and Sp1 and  the 




PTEN has four primary structural domains. On the 
amino terminus is the lipid and protein phosphatase 
domain, which is flanked adjacent to the C2 domain that 
is responsible for lipid binding and membrane 
localization. Next are two protein sequences rich in 
proline (P), glutamic acid (E), serine (S), and threonine 
(T) (PEST) domains that regulate protein stability.   
Lastly, PTEN has a PDZ domain, which helps facilitate 
protein-protein interactions. Mutations within the 
phosphatase domain have been reported to nullify the 
endogenous function of PTEN [31, 35]. Thus PTEN is 
an enticing therapeutic target for activation since it is 
frequently inactivated in many human cancers through 
point mutations as well as other means (e.g., promoter 
hypermethylation, gene deletion) and its inactivation 
results in elevated Akt activity and abnormal growth 
regulation [31, 35]. Moreover, PTEN can be inactivated 
by phosphorylation and oxidation in human cancer and 
which results in elevated Akt activity and abnormal 
growth regulation [31,35,36]. Thus, drugs reactivating 
PTEN could potentially be very useful in some types of 
tumors driven by PTEN inactivation. 
 
Another negative regulator of the PI3K pathway is the 
PH domain leucine-rich repeat protein phosphatase 
(PHLPP). PHLPP dephosphorylates S473 on Akt which 
induces apoptosis and inhibits tumor growth [37]. Two 
other phosphatases, SH2 domain-containing inositol 
5’phosphatase (SHIP)-1 and SHIP-2, remove the 5-
phosphate from PtdIns(3,4,5)P3  to produce 
PtdIns(3,4)P2 [38-41]. Mutations in these phosphatases, 
which eliminate their activity, can lead to tumor 
progression.  Consequently, the genes encoding these 
phosphatases are referred to as anti-oncogenes or tumor 
suppressor genes.   
 
Next we discuss some of the key downstream targets of 
Akt that can also contribute to abnormal cellular growth 
and are key therapeutic targets [4,19,35,42-47]. Akt-
mediated regulation of mTOR activity is a complex 
multi-step phenomenon. Some of these targets and how 
they interact with the Ras/PI3K/PTEN/Akt/mTOR and 
Ras/Raf/MEK/ERK pathways are indicated in Figure 3.  
Akt inhibits tuberous sclerosis 2 (TSC2 or hamartin) 
function through direct phosphorylation [4,19,35,42]. 
TSC2 is a GTPase-activating protein (GAP) that 
functions in association with the putative tuberous 
sclerosis 1 (TSC1 or tuberin) to inactivate the small G 
protein Rheb [4,19,35,43,44]. TSC2 phosphorylation by 
Akt represses GAP activity of the TSC1/TSC2 complex, 
allowing Rheb to accumulate in a GTP-bound state. 
Rheb-GTP then activates, through a mechanism not yet 
fully elucidated, the protein kinase activity of mTOR 
when complexes with the Raptor (Regulatory associated 
protein of mTOR) adaptor protein, DEPTOR and 
mLST8, a member of the Lethal-with-Sec-Thirteen 
gene family, first identified in yeast [4,19]. The 
mTOR/Raptor/mLST8 complex (mTORC1) is sensitive 
to rapamycin and, importantly, inhibits Akt via a 
negative feedback loop which involves, at least in part, 
p70S6K [44]. This is due to the negative effects that 
p70
S6K has on IRS1 [43] (see Figure 3). 
 
The mechanism by which Rheb-GTP activates 
mTORC1 has not been fully elucidated yet, however it 
requires Rheb farnesylation and can be blocked by 
farnesyl transferase (FT) inhibitors. It has been 
proposed that Rheb-GTP would relieve the inhibitory 
function of FKBP38 (another component of mTORC1) 
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However, more recent investigations did not confirm 
these findings [45]. 
 
Nevertheless, Akt also phosphorylates proline-rich Akt-
substrate-40 (PRAS40), an inhibitor of mTORC1, and 
by doing so, it prevents the ability of PRAS40 to 
suppress mTORC1 signalling (recently reviewed in 
[4,19,44]). Thus, this could be yet another mechanism 
by which Akt activates mTORC1. Moreover, PRAS40 
is a substrate of mTORC1 itself, and it has been 
demonstrated that mTORC1-mediated phosphorylation 
of PRAS40 facilitates the removal of its inhibition on 
downstream signaling of mTORC1 [4,19,44]. Also 
Ras/Raf/MEK/ERK signaling positively impinges on 
mTORC1. Indeed, both p90
Rsk-1 and ERK 1/2 
phosphorylate TSC2, thus suppressing its inhibitory 
function [4,19,44] (See Figure 3). Moreover, recent 
evidence has highlighted that, in solid tumors, 




The relationship between Akt and mTOR is further 
complicated by the existence of the mTOR/Rictor 
complex (mTORC2), which, in some cell types, 
displays rapamycin-insensitive activity. mTORC2 has 
been found to directly phosphorylate Akt on S473 in 
vitro and to facilitate T308 phosphorylation. Thus, 
mTORC2 can function as the elusive PDK-2 which 
phosphorylates Akt on S473 in response to growth 
factor stimulation [47]. Akt and mTOR are linked to 
each other via positive and negative regulatory circuits, 
which restrain their simultaneous hyperactivation 
through a mechanism involving p70
S6K and PI3K 
[4,19,35,44,48-55]. Assuming that equilibrium exists 
between these two complexes, when the mTORC1 
complex is formed, it could antagonize the formation of 
the mTORC2 complex and reduce Akt activity [44-46]. 
Thus, at least in principle, inhibition of the mTORC1 
complex could result in Akt hyperactivation. This is one 
problem associated with therapeutic approaches using 
rapamycin that block some actions of mTOR but not all. 
 
mTOR is a 289-kDa S/T kinase. It regulates translation 
in response to nutrients and growth factors by 
phosphorylating components of the protein synthesis 
machinery, including p70
S6K and eukaryotic initiation 
factor (eIF)-4E b inding protein-1 (4EBP-1), the latter 
resulting in release of the eukaryotic initiation factor-4E 
eIF-4E, allowing eIF-4E to participate in the assembly 
of a translational initiation complex [4,19,35,44]. 
p70S6K phosphorylates the 40S ribosomal protein S6, 
(rpS6), leading to active translation of mRNAs 
[4,19,35,44]. Integration of a variety of signals 
(mitogens, growth factors, hormones) by mTOR assures 
cell cycle entry only if nutrients and energy are 
sufficient for cell duplication [4, 48-52]. Therefore, 
mTOR controls multiple steps involved in protein 
synthesis, but importantly enhances production of key 
molecules such as c-Myc, cyclin D1, p27
Kip1, and 
retinoblastoma protein (pRb) [35].  
 
mTOR also controls the translation of hypoxia-
inducible transcription factor-1 (HIF-1) mRNA 
[51,52]. HIF-1 upregulation leads to increased 
expression of angiogenic factors such as vascular 
endothelial growth factor (VEGF) and PDGF [4]. 
Moreover, HIF-1 regulates the glycolytic pathway by 
controlling the expression of glucose-sensing molecules 
including glucose transporter (Glut) 1 and Glut3 [51]. 
By regulating protein synthesis, p70S6K and 4E-BP1 
also control cell growth and hypertrophy, which are 
important processes for neoplastic progression. Hence 
targeting the mTOR pathway could have many effects 
on the regulation of cellular growth.  
 
Many of the mRNAs encoding the previously 
mentioned genes contain 5’untranslated regions which 
are G+C rich and difficult to translate and referred to as 
weak mRNAs [35]. 4EP-B1 forms a complex with these 
mRNAs and other binding factors allowing the 
translation of these weak mRNAs [35,53-58]. 
Rapamycin and mTOR kinase inhibitors suppress the 
translation of these critical mRNAs involved in cell 
survival and growth.   
 
Control  of  Apoptotic  Regulatory  Molecules  by          
the Ras/Raf/MEK/ERK and Ras/PI3K/Akt/mTOR 
Pathways 
 
These two pathways regulate the activity of many 
proteins involved in apoptosis. In the following section, 
we will mainly discuss the effects of these pathways 
elicited  by post-translational mechanisms [2, 3, 58-62], 
although it should be noted that both ERK and Akt also 
phosphorylate transcription factors that influence the 
transcription of the Bcl-2 family of genes as well as 
other important genes involved in the regulation of 
apoptosis [2, 4, 35, 60-62]. Many of the effects of the 
Ras/Raf/MEK/ERK and Ras/PI3K/Akt/mTOR 
pathways on apoptosis are mediated by ERK or Akt 
phosphorylation of key apoptotic effecter molecules 
(e.g., Bcl-2, Mcl-1, Bad, Bim, CREB, Foxo, Caspase-9 
and many others) [2, 4, 35, 59-62]. In addition, both 
pathways regulate the translation of weak mRNAs. 
ERK, p90
Rsk-1, MNK1/2 and p70S6K regulate the 
phosphorylation of many of the proteins involved in the 
key complex required for the translation of the weak 
mRNAs [35,44,56,57]. In some cases, members of the 
two pathways (e.g., p90
Rsk-1 and p70
S6K) will phosphor- 
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the same site e.g. ribosomal protein S6 (rpS6) [57, 58]. 
However, the kinetics of phosphorylation of rpS6 by the 
two kinases differs. Thus these two pathways regulate 
the activity of this translation complex which is 
responsible for the translation of certain weak mRNAs 
involved in regulation of apoptosis. Mcl-1 is an 
example of a weak mRNA and it plays key roles in the 
regulation of apoptosis. 
 
Aberrant regulation of apoptosis is critically implicated 
in cancer as well as many other diseases (e.g., 
inflammation, auto-immune diseases). Therefore 
controlling the activity of the Ras/Raf/MEK/ERK and 
Ras/PI3K/PTEN/Akt/mTOR pathways have been keen 
pharmaceutical objectives for many years. The activity 
of many key components in apoptotic cascades is 
sensitive to inhibitors that target these pathways.  
 
Akt regulates the apoptotic response to a variety of 
stimuli via its ability to interact with a number of key 
players in the apoptotic process [2,4,61,62].  Akt can 
directly phosphorylate BAD on S136, causing its 
inactivation preventing it from interacting with anti-
apoptotic members of the Bcl-2 family of proteins (Bcl-
2, Bcl-XL) [29,62].  Activated Akt can inhibit the 
release of cytochrome c from the mitochondria, which 
is a potent activator of the apoptotic caspase cascade
 
[59].  The Akt target, Foxo-3 is capable of upregulating 
Fas ligand (Fas-L) and Bim, two very important 
molecules that are potent inducers of apoptosis; 
however, when inactivated by Akt, Foxo-3 is localized 
to the cytosol where it is unable to augment expression 
of these genes [28,60]. Akt can also phosphorylate Bim 
which inhibits its proapoptotic activity [61]. In concert, 
these events caused by Akt activation affect the survival 
status of the cell.  
 
Frequent Oncogenic Mutations at Members of these 
Pathways Result in Activation: Rationale for 
Therapeutic Targeting of these Pathways 
 
Effective targeting of signal transduction pathways 
activated by mutations and gene amplification may be 
an appropriate approach to limit cancer growth, 
metastasis, drug resistance as well as aging. The 
Ras/Raf/MEK/ERK and Ras/PI3K/PTEN/Akt/mTOR 
pathways can be activated by mutations/       
amplifications of upstream growth factor receptors. The 
abnormal production of growth factors can result in 
receptor activation which in turns mobilizes the 
Ras/Raf/MEK/ERK and Ras/PI3K/PTEN/Akt/mTOR 
cascades. An illustration of some of the receptors, 
exchange factors, kinases and phosphatases that are 
mutated/amplified in human cancer and how they may 
impact the Ras/Raf/MEK/ERK and 
Ras/PI3K/PTEN/Akt/mTOR cascades is presented in 
Figure 4.   
 
Perhaps one of the biggest advances in medical science in 
the 1980’s was the confirmation of the proto-oncogene 
hypothesis, that predicted that the human genome contains 
genes related to viral oncogenes which when mutated 
could cause human cancer [4,7,19,35,62-84]. Key       
genetic  members  of  the  Ras/Raf/MEK/ERK  pathway           
[e.g.,  RAS,  RAF), MEK (rarely) [81-84], the 
downstream transcription factor (ETS) the 
Ras/PI3K/PTEN/Akt/mTOR (e.g.,  PIK3CA,  AKT, 
PTEN) pathway and upstream receptors (e.g.,  ERBB1 
(EGF-R), ERBB2 (HER2), PDGFR, KIT, FLT3, FMS) 
were shown to fulfill this hypothesis as they were 
sometimes mutated/amplified/deleted in specific human 
cancers. The RAS, RAF, PIK3CA, AKT, ERBB1, KIT, 
FMS  and ETS oncogenes are also contained as viral 
oncogenes in the genomes of certain retroviruses that 
cause cancer in animals [2,7,35,62]. Furthermore, 
genetic mutations at these cellular oncogenes often alter 
sensitivity to specific targeted therapeutic approaches.  
Thus many of the genes in these two signal transduction 
pathway can cause cancer under the appropriate 
conditions.  
 
Mutation of Upstream Receptors that Activate the 
Ras/Raf/MEK/ERK and Ras/PI3K/Akt/mTOR 
Pathways in Human Cancer 
 
Amplification/overexpression of HER2 [human epidermal 
growth factor receptor, a.k.a., c-ErbB-2, (ERBB2)] is an 
important cause of sporadic breast cancer that occurs in 
approximately 30% of breast cancer. HER2 is a receptor 
tyrosine kinase (RTK) [85]. HER2 can heterodimerize 
with c-ErbB-3 which has six docking sites for PI3K. 
While a normal breast cell possesses 20,000 to 50,000 
HER2 molecules, amplification of this gene in HER2+ 
cancers can increase levels of HER2 up to 2,000,000 
molecules per cell [85]. Overexpression of HER2 is 
linked to comedo forms of ductal carcinoma in situ 
(DCIS) and occurs in approximately 90% of these cases. 
HER2  overexpression  will  lead  to  increased        
expression of both the Ras/PI3K/Akt/PTEN/mTOR and 
Ras/Raf/MEK/ERK pathways. Association of genes that 
regulate signal transduction pathways with breast cancer 
implies an important role of these pathways in neoplasia. 
 
In acute myeloid leukemia (AML), activation of the 
Ras/Raf/MEK/ERK and Ras/PI3K/Akt/mTOR pathway 
can result from mutated upstream targets such as class 
III RTKs. These include point mutations such as FLT3-
internal tandem duplications (FLT3-ITD) and mutated 
c-KIT,  which  are  present   in   35-40%   of  all  AML  
   


















































[2,4,35,62]. Mutations in upstream signaling molecules 
such as KIT and FLT3 are believed to activate the 
downstream signal transduction cascades, such as 




















































Mutations at RAS in Human Cancer 
 
Mutations that lead to expression of constitutively-
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frequency of RAS mutations and other key genes in the 
Ras/Raf/MEK/ERK and Ras/PI3K/PTEN/Akt/mTOR 
pathways in various types of cancers is presented in 
Table 1.  Often point mutations are detected in RAS 
genes in cancer cells from patients which enhance Ras 
activity. Genome RAS amplification or overexpression 
of Ras, perhaps due to altered methylation of its 
promoter region, are also detected in some tumors 
[7,63-69]. In cholangiocarcinoma, KRAS gene 
mutations have been identified in 45% of examined 
tumors [7]. Ras mutations are present in up to 20% of 
AML [67] and are another major cause of activation of 
this cascade. The frequency of KRAS mutations is very 
high (~80%) in advanced pancreatic cancers [7,63]. 
Mutations that result in increased Ras activity often 
perturb the Raf/MEK/ERK and also the 
PI3K/PTEN/Akt/mTOR cascades [7].  
 
A key event in the activation of the Ras protein is 
farnesylation. Inhibitors that target the enzyme farnesyl 
transferase (FT) have been developed with the goal of 
targeting Ras [2]. Clinical testing of FT inhibitors 
(FTIs) unfortunately has yielded disappointing results. 
The lack of usefulness of FTIs may be due to multiple 
reasons. First, there are many proteins that are regulated 
by FT. Second, although H-Ras is exclusively modified 
by FT and K-Ras to a lesser extent, N-Ras can also be 
modified by geranylgeranyltransferase  (GGT).         
This modified N-Ras is still able to support the 
biological requirement of Ras in the cancer cell. 
Geranylgeranylation of K-Ras and N-Ras become 
critical only when farnesylation is inhibited. The 
majority of RAS mutations in humans occur in KRAS, 
which is followed by NRAS [7,67]. The mutation rate at 
HRAS is a distant third [7]. Hence, it is very possible 
that the effects that FTIs had in initial clinical trials 
were not due to inhibition of mutant RAS genes present 
in the cell, but in fact resulted from non-specific effects 
which are related to the first point mentioned. Another 
important target of FTIs is the Rheb protein (Ras 
homologue enriched in brain) (See Figure 2). Rheb, 
another GTP binding/exchange protein, plays key roles 
in regulating mTORC1 and controlling the efficiency of 
protein translation [4,19,35].  
 
Mutations at RAF in Human Cancer 
 
Prior to 2003, it was believed that the RAF oncogenes 
were not frequently mutated in human cancer. There are 
three RAF genes in humans, (ARAF, BRAF and CRAF 
(a.k.a. Raf-1) encoding three distinct proteins with 
diverse and common functions. With the advent of 
improved methods of DNA sequencing, it was 
demonstrated that BRAF is frequently mutated in 
melanoma (27 to 70%), papillary thyroid cancer (36 to 
53%), colorectal cancer (5 to 22%), cholangiocarcinoma 
(22%), ovarian cancer (30%), and a small minority of 
lung cancer patients (1-3%) [70-75]. BRAF mutation 
occurs in approximately 7% of all cancers [70-73]. In 
contrast,  CRAF and ARAF are not believed to be 
frequently mutated in human cancer [80-81].  
 
It was proposed that the structures of B-Raf, Raf-1 and 
A-Raf kinases may dictate the ability of activating 
mutations to occur at, and be selected in, the genes 
encoding these proteins, which can permit the selection 
of oncogenic forms [75]. These predictions have arisen 
from the solved structure of B-Raf [75]. Like many 
enzymes, B-Raf is proposed to have small and large 
lobes, which are separated by a catalytic cleft. The 
structural and catalytic domains of B-Raf and the 
importance of the size and positioning of the small lobe 
may be critical in its ability to be stabilized by certain 
activating mutations. In contrast, the functionally 
similar mutations in ARAF and CRAF are not predicted 
to result in small lobe stabilization, this may prevent or 
hinder the selection of mutations at ARAF and CRAF, 
which would result in activated oncogenes [75]. 
 
The most frequent mutation detected at the BRAF gene 
is a change at amino acid 600, which converts a Val to 
Glu (Val600→Glu, V600E) [72]. This BRAF mutation 
accounts for > 90% of the BRAF mutations found in 
melanoma and thyroid cancer. BRAF mutations may 
arise in certain cells that express high levels of B-Raf as 
a result of hormonal stimulation. Certain hormonal 
signaling events will elevate intracellular cAMP levels, 
which result in B-Raf activation, leading to 
proliferation. Melanocytes and thyrocytes are two such 
cell types that have elevated B-Raf expression, as they 
are often stimulated by the appropriate hormones [76]. 
Moreover, it is thought that B-Raf is the most important 
kinase in the Ras/Raf/MEK/ERK cascade [75]. In some 
models, wild-type (WT) and mutant B-Raf are     
proposed to activate Raf-1, which then activates MEK 
and ERK [77,78]. A number of pharmaceutical and 
biotechnological companies have developed inhibitors 
that specifically target mutant B-Raf alleles (mutant-
allele specific inhibitors), which do not inhibit WT B-
Raf [3]. 
 
In many cancers with BRAF mutations, the mutations 
are believed to be initiating events and also the           
driver mutations, but are not sufficient for complete 
neoplastic transformation [35,65,66,72-75]. Mutations 
at other genes (e.g., in components of the 
Ras/PI3K/PTEN/Akt/mTOR pathway) have been 
hypothesized to be also necessary for malignant 
transformation in some  cancers.  Moreover,  there  may 
   















































































































Mutations of the Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Pathways in Human Cancer 
Gene  Cancer Mutated At  Approximate Reported Frequency  Reference 
RAS genes can be activated by point mutations, gene amplifications and other mechanisms. 
RAS  Many different types 




20-25% all human cancers, 
KRAS mutations account for 
about 85%, NRAS for about 
15%, HRAS for <1%. 
7 
KRAS  Pancreatic 90%  7 
HRAS, KRAS, 
NRAS 
Thyroid (papillary)  60%  7 
HRAS, KRAS, 
NRAS 
Thyroid (follicular)  55%  7 
KRAS  Colorectal 45%  7 
KRAS, NRAS  Seminoma 45%  7 
NRAS, KRAS  Myelodysplastic syndrome  40%  7 
KRAS  Non Small Cell Lung 
Carcinoma 
35% 7 
NRAS  Acute myelogenous 
leukemia 
30% 7 
NRAS  Liver 30%  7 
KRAS  Endometrial 20%  7 
NRAS  Melanoma 15%  7 
HRAS  Bladder 10%  7 
HRAS  Kidney 10%  7 
      
BRAF is activated in approximately 7% all cancers, highest in melanoma, often activated by point 
mutations. 
BRAF  Melanoma 27-70%  72 
BRAF  Papillary Thyroid   36-53%  72 
BRAF  Serous Ovarian  30%  72 
BRAF  Colorectal 5-22%  72 
      
PIK3CA is often activated by point mutations, also by gene amplification. 
PIK3CA  One of the most frequently 
mutated kinases in human 
cancer 
>30% solid cancers  106, 110 
PIK3CA  Breast  8-40%  106, 108, 110 
PIK3CA  Endometrial 23-36%  106,  110 
PIK3CA  Hepatocellular  36%  106, 108, 110 
PIK3CA  Colon 19-32%  110 
PIK3CA  Prostate 29%  31 
PIK3CA  Glioblastoma 5-27%  106,  110 
PIK3CA  Head/Neck Squamous Cell  33%  106, 110 
   














































































































PIK3CA  Gastric 25%  106,  110 
PIK3CA  Urinary Track  17%  31 
PIK3CA  Anaplastic 
Oligodendroglioma 
14% 106,  110 
PIK3CA  Ovarian 6-12%  110 
PIK3CA  Intraductal Papillary 
Mucinous Neoplasm 
Carcinoma of the pancreas 
11% 110 
PIK3CA  Upper Digestive Track  10%  31 
PIK3CA  Stomach 8%  31 
PIK3CA  Esophagus 7%  31 
PIK3CA  Oral Squamous Cell  7%  110 
PIK3CA  Pancreas 6%  31 
PIK3CA  Medulloblastoma 5%  110 
PIK3CA  Lung 4%  110 
PIK3CA  Hematopoietic & Lymphoid  4%  31 
PIK3CA  Skin 3%  31 
PIK3CA  Anaplastic Astrocytoma  3%  110 
PIK3CA  Thyroid 2%  31 
      
PTEN often inactivated by deletion, gene methylation, protein stability and other genetic mechanisms. 
PTEN  Endometrial   38%  31 
PTEN  Central nervous system   20%  31 
PTEN  Skin 17%  31 
PTEN  Prostate 14%  31 
PTEN  Colon 9%  31 
PTEN  Urinary track  9%  31 
PTEN  Lung 8%  31 
PTEN  Ovary 8%  31 
PTEN  Breast 6%  31 
PTEN  Hematopoietic & Lymphoid  6%  31 
PTEN  Thyroid 5%  31 
PTEN  Stomach 5%  31 
PTEN  Liver 5%  31 
PTEN  Upper aerodigestive track  4%  31 
PTEN  Esophagus 1%  31 
PTEN  Pancreas 1%  31 
      
AKT is infrequently mutated in human cancer but AKT2 gene can undergo amplification in certain 
cancers. 
AKT1  Thryoid 5%  www.sanger.ac.uk/perl. 
genetics/CGP/cosmic 
AKT1  Breast 3%  www.sanger.ac.uk/perl. 
genetics/CGP/cosmic 






























be certain situations where certain potent BRAF 
mutations (Val
600→Glu) and RAS mutations are not 
permitted in the same cell, as they might result in 
hyperactivation of Ras/Raf/MEK/ERK signaling and 
expression, which could lead to cell cycle arrest [75]. In 
contrast, there are other cases that require both BRAF 
and  RAS mutations for transformation. The BRAF 
mutations in these cases may result in weaker levels of 
B-Raf activity which is insufficient for abnormal 
proliferation [65,66,75,77,78]. It should be pointed out 
that RAS mutations may also result in activation of the 
Ras/PI3K/Akt/mTOR pathway. 
 
Different BRAF mutations have been mapped to various 
regions of the B-Raf protein. Mutations at BRAF that 
result in low kinase activity may signal through Raf-1 
[75,77,78]. Heterodimerization between B-Raf and Raf-
1 proteins may allow the impaired B-Raf to activate 
Raf-1. Other mutations, such as Asp
593→Val, may 
activate alternative signal transduction pathways [75]. 
 
One study has observed that mutated alleles of CRAF 
are present in therapy-induced acute myelogenous 
leukemia (t-AML) [80]. This t-AML arose after 
chemotherapeutic drug treatment of breast cancer 
patients. The mutated CRAF genes were transmitted in 
the germ line, thus, they were not spontaneous 
mutations in the leukemia, but they may be associated 



























breast cancer patients studied. Subsequent studies 
demonstrated that blast cells from patients with the 
CRAF germline mutations also had loss of the tumor 
and metastasis suppressor Raf kinase inhibitor protein 
(RKIP) [81]. The importance of RKIP was determined 
by transfection experiments with either siRNA directed 
against RKIP or expression vectors overexpressing 
RKIP [81]. The levels of RKIP were determined to 
influence the levels of CRAF-mediated transformation 
as high levels of RKIP suppressed CRAF-mediated 
transformation, while low levels enhanced CRAF-
mediated transformation [81]. Decreased RKIP 
expression has also been observed in some cutaneous 
squamous cell carcinomas which also displayed 
decreased BRAF expression [79]. Thus mutation at both 
BRAF and CRAF have been detected in certain cancer 
patients and other studies have shown that the levels of 
mutant and WT B-Raf, Raf-1 and RKIP will influence 
the levels of transformation observed, hence there is a 
strong basis for the development of Raf inhibitors [3]. 
 
Mutations downstream of Raf in the Ras/Raf/ 
MEK/ERK cascade have not been frequently detected 
in human cancer although there are some rare germline 
mutations detected at MEK1 and MEK2 in 
cardiofaciocutaneous syndrome (CFC)  [82].    There    
are also mutations at other components of the 
Ras/Raf/MEK/ERK pathway including KRAS and 
BRAF in CFC. There are mutations at components of 
AKT1  Ovary 1%  www.sanger.ac.uk/perl. 
genetics/CGP/cosmic 
AKT1  Urinary track  1%  www.sanger.ac.uk/perl. 
genetics/CGP/cosmic 
AKT1  Prostate 1%  www.sanger.ac.uk/perl. 
genetics/CGP/cosmic 
AKT1  Large Intestine  1%  www.sanger.ac.uk/perl. 
genetics/CGP/cosmic 
AKT1  Hematopoietic & Lymphoid 
tissue 
1%  www.sanger.ac.uk/perl. 
genetics/CGP/cosmic 
AKT2  Head and Neck squamous 
cell carcinomas 
30% amplified  31 
AKT2  Pancreatic 20%  amplified  31 
AKT2  Ovarian 12%  amplified  31 
AKT2  Breast 3%  amplified  31 
      
TSC1/TSC2 is inactivated by point mutations, deletion and other genetic mechanisms. Only TSC1is 
associated with some human cancers. 
TSC1  Urothelial Carcinoma  15%  159 
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and Noonan syndromes, including: SOS, and PTPN11 
(Shp2) in Noonan syndrome and HRAS mutations in 
Costello syndrome [83]. These germline mutations 
confer sensitivity to MEK inhibitors. MEK1 but not 
ERK2 mutations have been observed in some 
melanomas and colon carcinomas [84].   
 
Activation of the Ras/Raf/MEK/ERK Cascade in the 
Absence of Mutations in the Pathway 
 
Hepatocellular carcinoma (HCC) is the fifth most 
common cancer worldwide and the third most prevalent 
cause of cancer mortality, accounting for approximately 
6% of all human cancers and more than 600,000       
deaths annually worldwide [85,86]. Although the 
clinical diagnosis and management of early-stage HCC 
has improved significantly, HCC prognosis is still 
extremely poor. Therefore, investigating HCC 
pathogenesis and finding new diagnostic and treatment 
strategies is important. 
 
Signaling via the Ras/Raf/MEK/ERK cascade plays a 
critical role in liver carcinogenesis [86-91]. Although 
mutations of Ras and Raf occur infrequently in HCC, a 
recent study demonstrated that activation of Ras 
pathway occurred in 100% of HCC specimens analyzed 
when compared with non-neoplastic surrounding tissues 
and normal livers [91].  
 
In addition, activation of Ras/Raf/MEK/ERK pathway 
in HCC may be due to down-regulation of Ras 
inhibitors Sprouty and the Sprouty-related protein with 
Ena/vasodilator-stimulated phosphoprotein homology-1 
domain (Spred-1) and Spred-2 proteins [92,93]. It has 
been shown that the expression of Spred-1 and -2 in 
human HCC tissues is frequently decreased, in 
comparison to adjacent non-tumorous tissues. This 
decreased expression inversely correlated with the 
incidences of tumor invasion and metastasis [92]. 
Moreover, ectopic Spred expression inhibited HCC cell 
proliferation both in vitro and in vivo, which was 
associated with reduced ERK activation, suggesting that 
Spred could be both a novel prognostic factor and a new 
therapeutic target for human HCC [93].  
 
Down-regulation of RKIP expression is a major factor 
in activation of the Ras/Raf/MEK/ERK pathway     
during human hepatocarcinogenesis [94]. These     
studies indicate the complex interplay of various       
genes that serve to regulate the Ras/Raf/MEK/ERK 
pathway. Deregulation of their expression by various 
mechanisms (e.g., promoter methylation, point 
mutations, post-translational mechanisms) may result in 
Ras/Raf/MEK/ERK pathway activation in the absence 
of detectable mutations at either RAF or MEK. Hence, 
the Ras/Raf/MEK/ERK cascade is a therapeutic target 
in HCC [3,95,96]. 
 
Obesity is another important contributing factor for the 
development of HCC [97]. The important role of 
Ras/Raf/MEK/ERK signaling has also been suggested 
for HCC progression in obese patients. A possible 
explanation for risk associated between obesity and 
HCC comes from the study of Saxena et al., which for 
the first time demonstrated that leptin, a key molecule 
involved in the regulation of energy balance and body 
weight control, promotes HCC growth and invasiveness 
through activation of Ras/Raf/MEK/ERK signaling 
[98].  
 
Other well known risk factors for HCC such as hepatitis 
B and C v iruses (HBV and HCV) also utilize the 
Ras/Raf/MEK/ERK pathway for the control of 
hepatocyte survival and viral replication [99]. Among 
the four proteins encoded by HBV genome, HBx is 
involved in heptocarcinogenesis. HBx activates 
Ras/Raf/MEK/ERK signaling cascade [100]. Among 
HCV components, the core protein has been reported to 
activate the Ras/Raf/MEK/ERK pathway and thereby 
might contribute to HCC carcinogenesis [101, 102]. 
Therefore, these studies suggest that the 
Ras/Raf/MEK/ERK pathway is a novel therapeutic 
target that could be exploited for the treatment of HCC 
resulting from HBV and HCV infection. microRNAs 
(miRNAs) may play a key role in regulating HCV 
translation [103]. Protein translation is regulated by the 
Ras/Raf/MEK/ERK and Ras/PI3K/PTEN/Akt/mTOR 
pathways and may be a therapeutic target for HCC 
[104]. The interacting Wnt/-catenin pathway also has 
effects on HCC [105]. 
 
Mutations at PIK3CA in Human Cancer 
 
The PI3K p110 catalytic subunit (PIK3CA) gene is 
currently the most frequently mutated kinase in human 
cancer.  PIK3CA is mutated in approximately 25% of 
breast, 32% of colorectal, 30% of endometrial, 27% of 
brain, 25% of gastric, 4% of lung cancers [106-110] 
(Table 1). These mutations are clustered in small hot-
spot regions within the helical (E542, E545) and kinase 
(H1047) domains [106-110]. The locations of these 
mutations have been recently critically evaluated [110]. 
These mutations frequently result in activation of its 
kinase activity [110]. Furthermore increased expression of 
the Ras/PI3K/Akt/mTOR pathway also occurs frequently 
in some cancers as the PIKC3A gene is amplified in 
approximately 40% of ovarian cancers [109]. 
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mutation, inactivation or silencing of pathway 
components occurs in various malignancies, including 
liver cancer [111]. Deregulation of this pathway has 
clinical importance in HCC. For example, recent data 
from genomic sequence of HCC samples identified 
mutations in PIK3CA in 50% of patients with poor 
prognosis, survival length < 3 years following partial 
liver resection, and only 10% of the HCC patients with 
a good prognosis had mutation in PIK3CA [111]. The 
identified mutations were restricted to residues H1047 
in 61.1%, to E545 in 33.3%, and to E542 in 5.5% of 
cases, and as a consequence this result in gain of 
enzymatic function and consequently in oncogenic 
activity of PI3K [111].  
 
Mutations at PTEN in Human Cancer 
 
Germline PTEN mutations are present in approximately 
80% of patients with Cowden syndrome [112]. This 
disease, which is also known as multiple hamartoma 
syndrome, is another familial syndrome that includes 
many different types of cancer conditions including early 
onset breast cancer. Mutations have been reported to 
occur at PTEN in breast cancer in varying frequencies (5-
21%) [113,114]. Loss of heterozygosity (LOH) is 
probably more common (30%) [114]. Mutations at certain 
residues of PTEN, that are associated with Cowden’s 
disease, affect the ubiquitination of PTEN and prevent 
nuclear translocation. These mutations leave the 
phosphatase activity intact [115]. Inhibition of PTEN 
activity leads to centromere breakage and chromosome 
instability [34]. Thus PTEN has diverse activities.  
 
Akt and mTOR phosphorylation are frequently detected 
in ovarian and endometrial cancers. An early occurrence 
in endometrial cancer is the loss of functional PTEN 
activity by mutation or other mechanisms, this occurs in 
approximately 40-80% of patients [116]. Since the loss 
of PTEN results in activation of Akt, that in turn up-
regulates mTOR activity, cancer cells deficient in PTEN 
are thought to be major targets of mTOR inhibitors. 
 
The best evidence that strongly supports the connection 
between PTEN-suppression and liver carcinogenesis 
comes from genetic studies. All mice with PTEN-
deficient hepatocytes exhibited liver adenomas and 66% 
of them developed HCC [117]. In these mice, 
hepatocytes were hyperproliferative and displayed an 
abnormal activation of Akt [117]. Furthermore, 
although mutations in the PTEN gene rarely occur in 
HCC, frequent loss of heterozygosity of PTEN allele 
has been identified in 20-30% of HCC patients [118-
121]. In addition, down-regulation of PTEN expression 
may be partly due to PTEN promoter methylation [122]. 
PTEN expression plays a critical role in HCC 
progression and patient’s outcome. Patients with high 
expression of PTEN had a significantly better overall 
survival than patients with low PTEN expression [123]. 
As mentioned above, hepatitis viruses protect 
hepatocytes from apoptotic cell death by promoting the 
activation of Ras/PI3K/Akt/mTOR survival pathway 
[124,125]. Among the four proteins encoded by HBV 
genome, HBx has been reported to be involved in 
hepatocarcinogenesis. It has been reported that HBx 
expression downregulated PTEN expression in 
hepatocytes [125,125]. In contrast, PTEN expression in 
liver cells downregulated HBx-induced PI3K and Akt 
activities [126]. Therefore, these studies suggest the 
possible use of PTEN as a target in therapeutic 
approaches for the treatment of at least those HCC 
caused by HBV infection. 
 
In some cancer settings, PTEN and BRAF mutations 
appear to interact. Two recent papers have highlighted 
the hypothesis of mutant BRAF- and PTEN-loss-driven 
carcinogenesis in mouse models. In a study by Dhomen 
et al., inducible expression of B-Raf
V600E was sufficient 
to induce multiple melanocytic lesions including skin 
hyperpigmentation, dysplastic nevi and melanoma 
[127]. Tumor cells from these B-Raf
V600E mice 
displayed both melanoma growth and melanocyte 
senescence in this system. Approximately 70% of these 
mice developed melanomas that exhibited histological 
and molecular characteristics similar to that of human 
melanoma and were able to colonize the lungs in         
nude mice [127]. In contrast, another group of 
researchers generated mice that conditionally-expressed 
melanocyte-specific B-Raf
V600E that were only able to 
induce benign melanocytic hyperplasias and were 
unable to progress any further over a 15-20 month 
period [128].  However, B-Raf
V600E expression in a 
PTEN gene-silenced background led to the production 
of melanoma with 100% establishment, short latency 
and metastasis to lymph nodes and lungs.  This 
development was prevented by the treatment of mice 
with either the mTOR inhibitor rapamycin or the 
MEK1/2 inhibitor (PD0325901). Moreover, while 
combination treatment with rapamycin or PD0325901 
led to the reduction of established tumors, upon 
termination of drug treatment the melanomas 
reappeared the presence of drug resistant melanoma-
initiating cells in these mice. Overall, these two papers 
further validated the mutant B-Raf/MEK/ERK and the 
PI3K/Akt/mTOR pathways, as promising therapeutic 
targets in melanoma. 
 
Mutations and hemizygous deletions of PTEN have 
been detected in AML and non Hodgkin’s lymphoma 
(NHL) and other cancers [129,130]. Thus the PTEN 
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mutated in human cancer.  
 
Alterations of PTEN Expression in Human Cancer 
 
Phosphorylation (inactivation) of PTEN has been 
associated with increased Akt-activity. Although many 
groups have investigated the PTEN-phosphorylation 
status in leukemia and lymphoma, its relevance 
concerning Akt-activation is still not clear [129-133]. 
PTEN phosphorylation as well as low or absent PTEN 
expression has been observed in AML.  
 
Furthermore, the level of PTEN expression does not 
always correlate with the degree of phosphorylation         
of Akt [129]. Although the picture concerning           
PTEN-inactivation and corresponding Akt-activation is 
not clear, in vivo studies indicate, that PTEN 
dysregulation promotes leukemogenesis. PTEN-
deficient hematopoietic stem cells display dysregulated 
cell cycle progression, and the mice develop a 
myeloproliferative disease which leads to leukemic 
transformation [131]. In T-acute lymphoblastic 
leukemia (T-ALL), PTEN-downregulation is also 
closely correlated with Akt-activation [132,133]. To 
discern the role of PTEN for Akt-activation, it may be 
useful to exclude concomitant causes for Akt-activation 
such as mutant upstream targets and to include the 
investigation of regulators of PTEN such as c-Myc and 
Notch/Hes1 [132,133]. 
 
PTEN promoter methylation leads to low PTEN 
expression [134]. In one study, 26% of primary breast 
cancers had low PTEN levels that correlated with lymph 
node metastases and poor prognoses [135].  
 
Other mechanisms important in the regulation of PTEN 
are miRNAs. Certain miRNAs have been shown to 
regulate PTEN protein expression. mi-214 induces cell 
survival and may contribute to oncogenesis and drug 
resistance (see below) by binding the 3’untranslated 
region (3’UTR) of PTEN which prevents PTEN mRNA 
translation and leads of overexpression of downstream 
Akt [136]. 
 
Mutations at SHIP Phosphatase in Human Cancer 
 
The SHIP-1 phosphatase has been implicated as a 
suppressor of hematopoietic transformation as it 
basically can prevent Akt-activation [137]. SHIP-1-
deficient mice develop a myeloproliferative disease 
[138] and an inactivating point mutation (SHIP V684E) 
has been observed in approximately one of thirty AML 
cases [137]. Also another mutation,  SHIP Q1154L,  has  
been observed in AML, but was even less frequent (1 of 
192 cases) [138]. Though some studies confirmed, that 
SHIP-1 is a leukemia suppressor [137,138] it is unlikely 
that  SHIP1 mutations are a frequent cause of Akt-
activation in AML. Disruption of PTEN or SHIP activity 
by various genetic mechanisms could have vast effects on 
different processes affecting the sensitivity of different 
cancers to various therapeutic approaches. 
 
Mutations of AKT in Human Cancer 
 
The roles that Akt plays in cancer are complex. Akt can 
be activated by genetic mutations, genome 
amplifications and more commonly by mutations in 
upstream signaling components. Amplification of Akt-2 
was observed in human ovarian carcinomas [139]. 
Increased levels of Akt are detected in carcinomas of 
the breast, ovary and prostate and are associated with a 
poorer prognosis in comparison with tumors that do not 
display increased levels of expression. Akt is a member 
of a multi-gene family that consists of AKT1, AKT2 and 
AKT3. AKT1 has been reported to be mutated in some 
breast, colorectal, melanoma and ovarian cancers [140-
142] (see below). AKT2 is not mutated frequently in 
human cancer. AKT2 is amplified in certain cancers 
(e.g., 12.1% ovarian and 2.8% breast carcinomas) [142]. 
A recent report documents the mutation of AKT3 in 
some melanoma samples [143].  
 
AKT1 is mutated in 2 to 8% of breast, 6% of colorectal 
and 2% of ovarian cancers samples examined in one 
study [140]. This study documented an Akt mutation 
that results in a glutamic acid (E) for a lysine (K) 
substitution at amino acid 17 (E17K) in the PH domain. 
Cells with this AKT1 mutation have not been observed 
to have mutations at PIK3CA; a similar scenario is also 
frequently observed with RAS and BRAF mutations 
[144]. This AKT1  mutation alters the electrostatic 
interactions of Akt-1 which allows it to form new 
hydrogen bonds with the natural PtdIns ligand [140]. 
The PH domain mutation confers many different 
properties to the AKT1 gene. Namely the mutant AKT1 
gene has: 1) an altered PH domain conformation, 2) is 
constitutively-active, 3) has an altered cellular 
distribution as it is constitutively-associated with the 
cell membrane, 4) morphologically transforms Rat-1 
tissue culture cells and 5) interacts with c-Myc to 
induce leukemia in E-Myc mice (E = Enhancer of 
immunoglobulin   gene, Myc = Myc oncogene 
originally isolated in avian myelocytomatosis virus) 
[140]. This PH domain mutated AKT1 gene does not 
alter its sensitivity to ATP competitive inhibitors, but 
does alter its sensitivity to allosteric kinase inhibitors 
[140].   These   results  demonstrate  t hat  targeting  the  
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the activity of various AKT genes that have mutations in 
the PH domain.   
 
Alterations of Akt Expression in Human Cancer 
 
Akt is often upregulated in cancer cells and its 
overexpression is associated with a poor prognosis. 
Increased expression of Akt can result from activating 
PIK3CA mutations or elimination or decrease in PTEN 
activity. Elevated Akt expression has also been 
associated with the pathology of pancreatic, glioma and 
prostate cancers [145-148].  
 
Pancreatic cancer cells have elevated IGF-1R 
expression and it is well known that Akt regulates IGF-
1R expression [149]. This Akt effect on IGF-1R has 
been suggested to be responsible for the invasiveness of 
pancreatic cancer cells.  Active Src can also activate 
Akt, and both Src and Akt up-regulate IGF-1R 
expression in this cancer. It has been demonstrated that 
IGF-I is expressed in the surrounding stromal cells but 
not in the cancer cells. This IGF-1 expression may serve 
as a paracrine growth factor to activate the IGF-1R 
pathway and the downstream Ras/PI3K/Akt/mTOR 
pathway in pancreatic cells.  
 
Cyclooxygenase-2 (COX-2) is expressed at high levels 
in some primary endometrial tumors and is associated 
with an aggressive phenotype [150]. Akt is elevated and 
PTEN is often mutated in these cancers.  Recently, NF-
B activation has been shown to have oncogenic effects 
important in the control of apoptosis, cell cycle, 
differentiation and cell migration.  Akt may exert its 
effects through the NF-B pathway and COX-2 is the 
regulator of this pathway.  Akt regulates COX2 gene 
and protein expression in endometrial cancers. This 
study was undertaken to examine the involvement of 
Akt in the regulation of NF-B and COX-2 [150]. The 
expression of both inhibitor of NF-B (IB) and 
phosphorylated IB were increased in the cells 
containing mutant PTEN genes.  In contrast, there was 
no difference in NF-B protein abundance between the 
cell lines, which differed in PTEN gene status. IB 
phosphorylation by the PI3K pathway was inhibited by 
the PI3K inhibitors Wortmannin and LY294002. There 
was less NF-B nuclear activity, less COX-2 expression 
and more apoptosis after inhibition of the PI3K 
pathway. Dominant negative (DN) Akt blocked IB 
phosphorylation and decreased COX-2 expression. In 
contrast, introduction of constitutively-active Akt 
induced IB phosphorylation and up-regulated COX-2 
expression. 
 
When PTEN is mutated, Akt signals via the NF-B/IB 
pathway to induce COX-2 expression in endometrial 
cancer cells. COX-2 can inhibit apoptosis, increase 
angiogenesis,  and  promote  invasiveness.  COX-2       
also promotes inflammation/immunosuppression and 
conversion of procarcinogens into carcinogens that 
contribute to tumorigenesis and a malignant phenotype. 
This study demonstrated that Akt signals via the NF-
B/IB pathway to induce COX2 gene and protein 
expression in endometrial cancer [150]. 
 
Elevated Akt activity can also result in increased 
phosphorylation of mTOR. mTOR was found to be 
phosphorylated in AML blasts, along with its two 
downstream substrates, p70
S6K and 4EBP-1, in a 
PI3K/Akt-dependent fashion [151]. Nevertheless, others 
failed to detect any relationship between PI3K/Akt 
signalling upregulation and p70
S6K phosphorylation in 
AML primary cells [152]. This might occur via the 
Ras/Raf/MEK/ERK pathway activating mTOR via   
ERK phosphorylation [152]. The Ras/Raf/MEK/ERK 
pathway is frequently activated in AML [153]. Thus 
treatment of AMLs with Raf and MEK inhibitors is 
being activated investigated [3,154,155]. 
 
Akt is activated in HCC, which results in enhanced 
resistance to apoptosis through multiple mechanisms 
[101,156-158]. As an example, activation of the Akt 
pathway suppresses transforming growth factor-β 
(TGF-β) induced apoptosis and growth-inhibitory 
activity of CCAAT/enhancer binding protein alpha 
(CEBP-). Activation of Akt is a risk factor for early 
disease recurrence and poor prognosis in patients with 
HCC [156]. Several mechanisms may be responsible for 
the activation of Akt. The high frequency of PIK3CA 
mutations and/or its upregulation in patients with 
shorter survival might be responsible for the Akt 
hyperactivation found in HCC with poor prognosis 
[118-124]. Selective epigenetic silencing of multiple 
inhibitors of the Ras pathway seems also to be 
responsible for the activation of Akt found in HCC 
[111]. Moreover, impaired expression of PTEN is 
involved in the regulation of Akt activity. Activation of 
Akt signaling and reduced expression of PTEN has been 
reported in 40%–60% of human HCC cases [111,118-
124]. Some well known risk factors, HBV and HCV 
seem to utilize the Ras/PI3K/PTEN/Akt/mTOR 
pathway for the control of hepatocytes survival and 
viral replication [157,158]. Taken together, these data 
suggest that Ras/PI3K/Akt/mTOR pathway may 
represent an important therapeutic target for the 
treatment of HCC among patients with differing 
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Mutations in the tumor suppressor genes TSC1 and TSC2 
are associated with a dominant genetic disorder, tuberous 
sclerosis [42,159]. Patients with mutant TSC genes 
develop benign tumors (hamartomas). In contrast to 
Cowden’s patients who have germline mutations at PTEN 
and the patients have a high propensity to develop 
multiple malignancies, TSC patients rarely develop 
multiple malignant cancers, and if they do develop 
malignant cancers they are usually either renal cell 
carcinomas (RCCs) or angiomyolipomas [159]. This has 
been hypothesized to result from a lack of activation of 
Akt in cells that have mutant TSC1 or TSC2 as mTOR 
activity is expressed at higher levels which results in 
inhibition of Akt, perhaps via the effects of p70S6K on 
insulin regulated substrate-1 (IRS1) (Figure 3). TSC1 has 
been shown to be mutated in approximately 15% of 
urethelial carcinomas (bladder cancers) [159]. 
 
Altered Expression of Components Downstream of 
mTOR in Human Cancer 
 
mTOR regulates translation by phosphorylating 
components of the protein synthesis machinery, 
including p70S6K
  and 4E-BP1 (eukaryotic initiation 
factor 4E-binding protein 1) [160,161]. p70S6K 
phosphorylates the 40S ribosomal protein, rpS6, leading 
to active translation of mRNAs [4]. In contrast, 4E-BP1 
phosphorylation by mTORC1 on several amino acidic 
residues (S37; T46; S65; T70) results in the release of 
the eukaryotic initiation factor 4E (eIF4E) [5]. mRNAs 
differ in their ability to be translated; the length and 
sequence of the 5’ UTR largely dictates the efficiency 
with which an mRNA transcript will be translated. Most 
mRNAs contain short, unstructured GC-poor 5’ UTRs 
and are efficiently translated. In contrast, long, GC-rich 
sequences in the 5’ UTR often hinder the ability of the 
eIF-4E complex to efficiently scan and initiate 
translation at the start codon [4,19,35]. These are called 
weak mRNAs as previously discussed. Consequently, 
under normal circumstances these mRNAs are not 
efficiently translated, and are considered “weak” 
mRNAs [4,19,35]. However, upon Akt-mediated 
activation of mTOR, these latter mRNAs are highly and 
disproportionately translated. Interestingly, many of 
these weak mRNAs molecules encode oncogenic 
proteins involved in cell proliferation or survival (e.g., 
c-Myc, Mcl-1, cyclin-D, VEGF and survivin). These 
oncogenic mRNAs are therefore tightly regulated at the 
translation level and their accumulation in cancer cells 
strongly contributes to the malignant phenotype.  
 
Several key proteins that are overexpressed as a 
consequence of mTOR activation include: c-Myc [162-
164], cyclin D1 [164], and VEGF [165] and others.   
Cyclin D1 has been reported to be overexpressed in 
prostate cancer xenografts and metastases [166], while 
early stage prostatic lesions possess much lower levels 
of the protein [167]. A number of reports support the 
notion that mTOR signaling is a prominent feature of 
cancer progression and aging, as recurrent tumors have 
altered expression of a number of molecular targets of 
rapamycin including the above mentioned genes which 
encode “weak” mRNAs  [168-171].  Hence mTOR 
inhibitors such as rapamycin may be effective in cancer 
therapy. 
 
One central molecule involved in cell growth is         
p70S6K which is regulated by both the 
Ras/PI3K/PTEN/Akt/mTOR and Ras/Raf/MEK/ERK 
pathways [4]. The p70S6K gene is amplified in 
approximately 9% of primary breast cancers and elevated 
levels of its mRNA transcripts are found in about 41% of 
the tumors [173,174]. It is known that some PTEN-
deficient cells and tumors that are purported to grow in 
response to activated Akt are hypersensitive to mTOR 
inhibitors. p70S6K activity is reduced by mTOR 




Involvement of the Ras/Raf/MEK/ERK and 
Ras/PI3K/PTEN/Akt/mTOR  Pathways in Hormone-
Independent Prostate Cancer 
 
The progression of prostate cancer from androgen-
dependent to androgen-independent tumors involves the 
alteration of the androgen receptor and/or the activation 
of pro-survival pathways, namely those of the 
Ras/Raf/MEK/ERK and Ras/PI3K/PTEN/Akt/mTOR 
signaling cascades [177,178].  Research has shown that 
inhibition of one or both of these pathways has a more 
profound effect on tumor cell development and death 
making them very attractive as combinational targets in 
prostate cancer therapy.  In the study by Wu et al., cells 
from the androgen-dependent cell line LNCaP were 
able to differentiate into neuroendocrine type cells upon 
androgen withdrawal from the culture media [177].   
This differentiation was marked by a change in cellular 
morphology and expression of the chromogranin and 
neuron-specific enolase (NSE), as well as an increase in 
phosphorylated ERK and Akt.  Inhibition of the 
Ras/PI3K/PTEN/Akt/mTOR pathway with the PI3K 
inhibitor LY294002 and the mTOR inhibitor 
Rapamycin reduced the expression of these 
neuroendocrine specific cell markers however the use of 
the MEK inhibitor U0126 appeared to have no             
effect [177].  In another study, Nkx3.1;Pten mutant 
mice were used as a preclinical model for the effects 
that inhibition of both Ras/Raf/MEK/ERK and 
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hormone-dependent and -independent prostate cancer 
growth [178]. The Nkx3.1;Pten mutant mouse model 
resembles that of human prostate cancer progression in 
which spontaneous PIN lesions form and progress to 
adenocarcinomas and eventually hormone refractory 
tumors upon androgen deprivation.  Treatment of 
tumors from these mice both in vivo and in vitro with 
rapamycin and the MEK inhibitor PD0325901 were 
able to synergistically decrease their respective target 
pathway’s activation more effectively and at a lower 
IC50 compared to treatment with each agent alone [179].  
Interestingly, although combination inhibitor therapy 
was somewhat effective at reducing tumor size and 
proliferation in the androgen-intact mouse model, the 
highest reduction in tumor growth from therapy was 
observed in the androgen-deficient mice [178].  In 
addition to the mouse study these authors were able         
to  show,  using  human  patient  tissue  microarrays,           
that aberrant activation of some of the 
Ras/PI3K/PTEN/Akt/mTOR pathway components (Akt, 
mTOR, p70S6K) are frequent in progressed human 
prostate tumors.  In addition, activation of the 
Ras/Raf/MEK/ERK pathway coincides with a high 
percentage of these tumors as well, suggesting that 
combination inhibitor treatment along with hormone 
ablation could prove useful in human prostate cancer 
therapies [178]. 
 
Interactions of p53 and the Ras/Raf/MEK/ERK and 
PI3K/PTEN/Akt/mTOR pathways 
 
  Ras/Raf/MEK/ERK and Ras/PI3K/PTEN/Akt/mTOR 
pathways are often regulated by the tumor             
suppressor p53. Furthermore p53 activity is likewise 
regulated by the Ras/Raf/MEK/ERK and 
Ras/PI3K/PTEN/Akt/mTOR pathways. p53 is a critical 
tumor suppressor gene which encodes a transcription 
factor that is frequently mutated in human cancer [179-
195]. P53 regulates the transcription of many genes 
whose protein products play critical roles in cell cycle 
progression, apoptosis, senescence, quiescence and 
aging. p53 is often activated after chemotherapeutic 
drug treatment and DNA damage [182,183,193-195] 
There are complex interactions between p53, DNA 
damage responses and these two signaling pathways 
[180-195]. Akt can phosphorylate MDM-2 which leads 
to its proteasomal degradation and prevents it ability to 
interact with and destabilize p53 [4]. The p53 and 
MDM families of genes are critically involved in the 
response to DNA damage [183-185], apoptosis [185], 
senescence [186], metastasis [188], autophagy [190], 
chemosensitivity [191,195] and cellular aging 
[179,181,182]. Thus the ability to fine tune these 
pathways could significantly advance human health. 
MDM-2 inhibitors such as Nutlin-3A increase p53 
stability [179]. p53 can affect the transcription of the 
PTEN and other important gene involved in cell cycle 
regulation (e.g., p21
Cip-1), apoptosis (e.g., Bax, Noxa, 
Puma) and cellular senescence [e.g., Yippee-like-3 
(YPEL3)], [180,184-186,192]. Thus reactivation of p53 
expression could enhance PTEN gene expression and 
hinder activation of Akt.  
 
The Ras/Raf/MEK/ERK pathway can regulate p53 
activity and p53 can also induce the activity of key 
components of this pathway [196-198]. ERK can 
phosphorylate p53 and alter its activity. Moreover, 
chemotherapeutic drugs such as doxorubicin can induce 
the p53 activity that in turn can activate the expression 
of the discoidin domain receptor (DDR) which can 
induce Ras and the downstream Ras/Raf/MEK/ERK 
and Ras/PI3K/PTEN/Akt/mTOR pathways [196-198].  
 
In certain scenarios, increased p53 expression after 
chemotherapeutic drug treatment may lead to increased 
Ras/Raf/MEK/ERK and Ras/PI3K/PTEN/Akt/mTOR 
pathways activation, resulting in an undesired pro-
proliferative effect [195]. This may occur in certain 
cancer initiating cells (CICs) and be a component of 
their inherent drug resistance. In addition, Akt has 
critical roles in regulation of cell cycle progression 
[199-202] Thus in those therapeutic scenarios where 
increased p53 activity is desired, it may also be prudent 
to also consider treatment with either a Raf or MEK 
inhibitor to decrease the activation of this pro-
proliferative pathway.  
 
Novel Roles of the Ras/Raf/MEK/ERK and 
Ras/PI3K/PTEN/Akt/mTOR Pathways in Cancer 
and Aging 
 
In the previous sections, we have discussed the 
mechanisms of activation of the Ras/Raf/MEK/ERK 
and Ras/PI3K/PTEN/Akt/mTOR pathways in human 
cancers, predominantly by mutational based 
mechanisms. Recently the Ras/Raf/MEK/ERK and 
Ras/PI3K/PTEN/Akt/mTOR pathways have been 
shown to have roles in cancer stem cells, senescence, 
aging and sensitivity to targeted therapy [203-245]. 
These additional functions of these pathways expand 
their important in human health.    
 
An area of intense interest in cancer biology is the 
cancer  stem  cell,  more  appropriately  referred                
to as the cancer initiating cell (CIC) [203-211]. The 
concept that the Ras/Raf/MEK/ERK and 
Ras/PI3K/PTEN/Akt/mTOR pathways serve as key 
pathways in regulating CIC survival is beginning to 
emerge. CICs have unique properties as they can be 
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and hormonal based drugs [203]. However, under 
certain conditions, they resume proliferation and hence 
should be potentially susceptible to Ras, Raf, MEK, 
PI3K, Akt or mTOR inhibitors.  
 
The  PTEN gene has been shown to exert effects on 
CICs, especially in hematopoietic and breast cells [204-
209]. In conditional PTEN knock-out mice, upon 
inactivation of PTEN, there is a transient increase in 
hematopoietic CICs and a myeloproliferative disease 
develops and the mice subsequently develop leukemia 
after 4-6 weeks [204]. If the mice are treated with 
rapamycin, the myeloproliferative disorder and 
leukemia are prevented. The initial leukemic CICs that 
arise after conditional PTEN deletion by themselves are 
not able to induce leukemia upon transfer into severe 
combined immunodeficiency (SCID)-recipient mice, 
but if the leukemic CICs were derived from the PTEN-
conditional mice that had developed leukemia, they 
were able to transfer leukemia to the SCID-recipient 
mice, which could be prevented by rapamycin treatment 
[204]. Also the normal hematopoietic stem cells from 
the PTEN-conditional knock-out mice could repopulate 
the hematopoietic cell component of irradiated mice 
treated with rapamycin indicating that it is possible to 
selectively eliminate leukemic CICs. 
 
PTEN also plays important roles in breast CICs 
[205,206]. If PTEN is mutated, Akt phosphorylates and 
inactivates glycogen synthetase kinase 3 (GSK-3) 
which in turn regulates the activity of the Wnt/-catenin 
pathway [Figure 3], as -catenin is not phosphorylated 
by GSK-3 and not degraded. -catenin can    localize 
to the nucleus, perhaps due to Akt-mediated 
phosphorylation at S552 and exert its effects. -catenin 
can  then  promote  the  expression  of  many  genes        
such as cyclin D, c-Myc, SALL4 and peroxisome     
proliferator-activated receptor- (PPAR) which are 
important in cell survival and EMT. The 
Ras/PI3K/PTEN/Akt/mTOR pathway performs key 
roles in the regulation of the size of the Aldefluor-
positive cell population that are enriched in breast CICs. 
Treatment with the Akt inhibitor perifosine was able to 
target these cells both in in vitro and xenograft models 
[206]. In contrast, the chemotherapeutic drug docetaxel 
was unable to target the Aldefluor-positive cells and 
these cells were not sensitive to mTOR inhibitors, 
suggesting that the mTOR pathway was not involved in 
these breasts CIC. The studies by Korkaya et al. [206] 
indicate that targeting some breast CICs with perifosine 
may eliminate these cells that are responsible for tumor 
reappearance. Other studies have shown that breast 
CICs are resistant to chemotherapeutic drugs [212-214].  
 
We have observed that some drug resistant breast       
cells that express properties similar to CICs display 
elevated activation of the Ras/Raf/MEK/ERK and 
Ras/PI3K/PTEN/Akt/mTOR signaling cascades and that 
CICs can be isolated from these cell populations [215-
217]. Our recent data suggests these CICs are more 
sensitive to MEK and mTOR inhibitors than either the 
parental or drug resistant cells from which they were 
derived [215]. Targeting the Ras/Raf/MEK/ERK and 
Ras/PI3K/PTEN/mTOR pathways could be very 
important in terms of CIC elimination. 
 
Involvement of the Ras/Raf/MEK/ERK and 
PI3K/PTEN/Akt/mTOR Pathways in Suppression 
Cellular Senescence and Premature Aging 
 
The Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR 
pathways play key roles in regulation of diverse 
processes ranging from: autophagy DNA damage 
responses, cellular senescence and aging [217-237] 
Treatment of cells induced to undergo senescence with 
MEK, PI3K and mTOR inhibitors will prevent the 
induction of cellular senescence and aging [219-221]. 
These experiments have led to innovative hypothesis 
that cellular senescence results from the hyper-
activation of proliferative pathways. Drugs used to treat 
diabetes (e.g., Metformin) or inhibit signal transduction 
pathways (e.g., Raf, MEK, PI3K, mTOR inhibitors) can 
inhibit cellular proliferation and cellular aging [229-
234]. Similar effects on the prevention of cellular 
senescence were observed with Resveratol, the active 
component contained in the skins of red grapes which 
was shown to also inhibit mTOR and cellular 
senescence [229,230]. Additional studies have shown 
that the commonly-prescribed diabetes drug Metformin 
will also inhibit mTOR and prevent cellular aging 
[234]. Since both the Raf/MEK/ERK and 
PI3K/PTEN/Akt/mTOR pathways interact to regulate 
the activity of mTOR and downstream components of 
this pathway which are critical for both mRNA stability 
and protein translation, it is believed that by inhibiting 
some of these key pathways, it may be possible to 




Over the past 25 years, there has been significant 
progress in elucidating the involvement of the 
Ras/Raf/MEK/ERK and Ras/PI3K/PTEN/Akt/mTOR 
cascades in promoting cell growth, regulating apoptosis, 
chemotherapeutic drug resistance and more recently, 
cellular senescence and aging. Initial seminal studies 
performed in the late 70’s and early 80’s elucidated that 
oncogenes  were  present  in  the  genomes  of avian and  
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ErbB, Fms, Ras, PI3K, Akt, Src, Abl, Raf, Fos, Jun, Ets 
and NF-B (Rel) were subsequently identified as 
cellular genes which in some cases were captured by 
retroviruses. Now we know that these cellular genes are 
frequently abnormally regulated in human cancer. 
Furthermore mutations in human cancer often occur in 
upstream receptor genes such as EGFR, HER2, Flt-2, 
PDGFR, FMS, as well as chromosomal translocations 
(e.g., BCR-ABL, TEL-PDGFR) that serve to activate the 
Ras/Raf/MEK/ERK and Ras/PI3K/PTEN/Akt/mTOR 
pathways which have been discussed as playing critical 
roles in cellular proliferation in this review.  Hence       
the Ras/Raf/MEK/ERK and Ras/PI3K/Akt/mTOR 
pathways are important therapeutic targets. Both of 
these pathways also interact with the p53 and Wnt 
pathways, which also play critical roles in regulation of 
cell growth, aging, CICs and metastasis. Specific Raf, 
MEK, PI3K, Akt, mTOR and Mdm-2 inhibitors have 
been developed and represent promising therapies for 
cancer and other proliferative diseases including 
premature aging.  
 
Scientists and clinicians often have an intentionally 
narrow view of a particular topic. For example, cancer 
researchers predominately consider that Raf, MEK, 
PI3K, Akt and mTOR inhibitors will suppress the 
growth of malignant cancer cells. Yet MEK and mTOR 
and other inhibitors may also be useful in the treatment 
of diseases and disorders where there is abnormal 
cellular proliferation. Recent reports have also 
demonstrated that the suppression of the 
Ras/Raf/MEK/ERK and Ras/PI3K/PTEN/Akt/mTOR 
pathways may prevent the induction of cellular 
senescence and aging. Clearly, this later topic, aging, 
greatly enhances the potential clinical uses of these 
targeted therapeutic drugs. In conclusion, the 
Ras/Raf/MEK/ERK and Ras/ PI3K/PTEN/Akt/mTOR 
pathways are prime therapeutic targets for diverse 
human diseases as well as aging. 
 
Cancer therapy is often complex as there are relatively 
few cancers which proliferate in response to a single 
mutation preventing them from being treated with a 
mono-specific drug. One exception is the use of the 
drug Gleevec (Imatinb) for the treatment of chronic 
myeloid leukemia (CML). Although even with this 
therapeutic approach, resistance develops. Scientists 
and clinicians have developed newer BCR-ABL 
inhibitors (e.g., Dasatinib, Nilotinib, Bosutinib) which 
can reduce resistance which has also resulted in more 
through analysis and understanding of how the BCR-
ABL kinase functions and resistance can arise by 
additional genetic mutations. These studies on BCR-
ABL inhibitors have also paved the way for 
development of more effective inhibitors for other 
oncogenes. 
 
It is possible that activation of the Ras/Raf/MEK/ERK 
and Ras/PI3K/PTEN/Akt/mTOR survival pathways by 
additional mutations in upstream oncogenes may 
replace the tumor’s initial oncogene addition. This may 
complicate therapy as the tumor may no longer be 
responsive to treatment with a single inhibitor which 
targets the original oncogene responsible for malignant 
transformation as the cells now have additional 
downstream signalling pathways activated. In addition, 
the tumor cells may acquire subsequent mutations 
which make them resistant to inhibitors that target the 
original activated oncogene. Such mutations may occur 
in the original activated oncogene or in additional genes 
which are critical in anti-apoptotic survival cascades. 
These observations document the need for further 
elucidation of mechanisms of inhibitor resistance as 
well as the development of additional inhibitors which 
target either the mutated oncogene or other genes 
activated in the resistant cells. 
 
The activation of multiple signalling pathways by many 
oncogenes illustrates the need for the targeting of more 
than one signalling pathway. Although one inhibitor 
which targets one molecule in one pathway may 
initially appear to be effective in inhibiting tumor             
cell growth, the cell may adapt and be able to survive 
due to the activation of an additional signalling 
pathway. Although the Ras/Raf/MEK/ERK and 
Ras/PI3K/PTEN/Akt/mTOR pathways have distinct 
effects on cell proliferation, they have many common 
downstream targets that may be able to function in 
promoting survival in the absence of the corresponding 
functional pathway. In some cases resistance to small 
molecule  inhibitors  may  be  due  to  the  activation          
of an additional pathway that also serves to promote 
survival (e.g., PIK3CA and HRAS mutations can confer 
resistance to MEK inhibitors and other targeted 
therapeutics such as Erbitux and others) [238-245]. 
 
Most cancers are more complex and often the genes and 
events involved are either not known or difficult to 
counterbalance. Chemotherapy and radiotherapy can be 
effective in the treatment of certain tumors, however, 
often cancers become resistant to these approaches, 
perhaps due to the emergence of CICs [203,215-217]. 
Thus scientists and clinicians have endeavored to 
develop more specific therapies that target key 
pathways involved in cancer growth. In this respect, the 
Ras/Raf/MEK/ERK and Ras/PI3K/PTEN/mTOR/Akt 
pathways represent key therapeutic targets as they are 
often dysregulated by various mutations in cancer and 
these cascades control the activities of many proteins 
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pathways are already being targeted in certain cancer 
patients. However, usually the cancer patients being 
treated with inhibitors that target these cascades have 
diseases that often have poor prognoses. That being 
said, what are the pros and cons of targeting these 
pathways? Let us first consider the positive aspects of 
targeting these pathways. First, these pathways are 
frequently activated in human cancer, thus in many 
cases, targeting the cascades will suppress cell growth, 
in the absence of knowing the precise mutation(s) 
responsible for the cancer. Second, although the 
biochemical interactions of these pathways are quite 
complex, there is quite a bit of knowledge of how these 
pathways function. Third, some inhibitors which target 
key components in this pathway (e.g., rapamycin which 
targets mTOR) have undergone extensive evaluation in 
humans as they have been used to prevent allograft 
rejection in kidney and other transplant patients for 
many years. Fourth, targeting these pathways may 
prevent aging and cellular senescence.  
 
Now, let us summarize some of the cons of targeting 
these pathways. First, an obvious problem results         
from these pathways controlling the expression of     
many downstream targets (easily in the 1000’s),             
thus inhibiting these pathways will be detrimental in 
certain cells, unless it is possible to deliver the       
inhibitor to specifically the cancer cell. Second, the 
Ras/Raf/MEK/ERK and Ras/PI3K/PTEN/Akt/mTOR 
pathways cross regulate each other and other pathways 
including the Wnt/-cateinin pathway which is critical 
for many aspects of cellular growth and differentiation 
including the EMT. The Ras/Raf/MEK/ERK and 
Ras/PI3K/PTEN/Akt/mTOR pathways also regulate 
other pathways which have not been discussed in this 
manuscript. These other pathways include: the 
Jak/STAT, NF-κB and transforming growth factor- 
(TGF-) pathways which can be directly and indirectly 
regulated by ERK and Akt phosphorylation [62].  In this 
regards there will be a Ying-Yang effect, when one 
cascade is inhibited, components of the other pathway 
could be deregulated. Third, inhibitors that target these 
pathways are often cytostatic and not cytotoxic, that is 
somewhat logical as if these inhibitors were cytotoxic, 
there would be massive toxicity problems. To get 
around this problem, inhibitors targeting these pathways 
could be combined with cytotoxic chemotherapeutic 
drugs or radiation therapy that affects the rapidly 
growing cancer cell. In summary, the Ras/Raf/MEK/ 
ERK and Ras/PI3K/PTEN/Akt/mTOR cascades are 
complex, interacting pathways playing key roles in 
normal and malignant cell growth. These pathways are 
frequently activated by mutations in human cancer. 
They represent key therapeutic targets for cancer and 
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